Comparison
Armodafinil vs Nicotinamide Riboside
Side-by-side of Armodafinil and Nicotinamide Riboside. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Armodafinil
Armodafinil is the R-enantiomer sold as Nuvigil. Half-life 10-15 h, 150 mg standard dose, narcolepsy and shift-work approvals, Schedule IV.
Nicotinamide Riboside
Nicotinamide riboside (NR) is the most-studied NAD+ precursor in humans. Sold as Niagen by Chromadex; raises plasma NAD+ 30-60% at 250-1,000 mg/day.
Effects at a glance
Armodafinil
- •FDA approved in 2007 for narcolepsy, shift-work sleep disorder, and OSA residual sleepiness
- •R-enantiomer of modafinil; 150 mg armodafinil is roughly equivalent to 200 mg modafinil
- •Schedule IV controlled in the US; prescription-only globally
- •Longer terminal half-life of about 15 hours produces extended late-day wakefulness coverage
- •Same CYP3A4 induction as modafinil; reduces hormonal contraceptive efficacy
- •Side-effect profile and dermatologic risk warnings mirror modafinil
Nicotinamide Riboside
- •Most-studied NAD+ precursor in human trials; the original Niagen formulation by Chromadex
- •Plasma NAD+ rises 30-60% at 250-1,000 mg/day across multiple human PK trials
- •Martens 2018 reported reduced BP and arterial stiffness at 500 mg/day for 6 weeks
- •Dollerup 2018 found no insulin sensitivity change despite plasma NAD+ rise
- •Tissue NAD+ rise inconsistent; hard clinical endpoints not yet measured
- •Larger human safety database than NMN; comparable mechanistic effects
Side-by-side
| Attribute | Armodafinil | Nicotinamide Riboside |
|---|---|---|
| Category | pharmaceutical | supplement |
| Also known as | Nuvigil, R-modafinil, (R)-(-)-modafinil | NR, Niagen, nicotinamide riboside chloride |
| Half-life (hr) ↗ | 15 | 8 |
| Typical dose (mg) ↗ | 150 | 500 |
| Dosing frequency | daily, morning | daily, typically morning |
| Routes | oral | oral |
| Onset (hr) | 1 | 1 |
| Peak (hr) | 3 | 4 |
| Molecular weight | 273.35 | 255.25 |
| Molecular formula | C15H15NO2S | C11H15N2O5 |
| Mechanism | Weak dopamine reuptake inhibition plus downstream activation of histaminergic, noradrenergic, and orexinergic wake systems; R-enantiomer of modafinil with longer half-life. | NAD+ precursor via salvage pathway. Phosphorylated to NMN by nicotinamide riboside kinase (NRK), then converted to NAD+. Substrate for sirtuins, PARPs, and CD38. |
| Legal status | Schedule IV (US); prescription-only globally; not a supplement | OTC dietary supplement |
| WADA status | banned | allowed |
| DEA / Rx | Schedule IV | OTC supplement |
| Pregnancy | Not recommended | Insufficient data at supplement doses |
| CAS | 112111-43-0 | 1341-23-7 |
| PubChem CID | 9148206 | 439924 |
| Wikidata | Q4791953 | Q3343054 |
Safety profile
Armodafinil
Common side effects
- headache
- nausea
- dizziness
- anxiety
- insomnia (with later-day dosing)
- dry mouth
- mild blood pressure elevation
Contraindications
- recent myocardial infarction
- unstable angina
- left ventricular hypertrophy
- significant arrhythmia
- history of Stevens-Johnson syndrome
- psychotic disorders
- pregnancy
- concurrent MAOI use
Interactions
- hormonal contraceptives: CYP3A4 induction reduces contraceptive efficacy; use barrier method(major)
- cyclosporine: reduced cyclosporine levels via CYP3A4 induction(major)
- warfarin: CYP2C9 inhibition raises INR(moderate)
- phenytoin: CYP2C19 inhibition raises phenytoin levels(moderate)
- MAOIs: potential hypertensive reaction(major)
- classical stimulants: additive cardiovascular and sleep-disruption effects(moderate)
Nicotinamide Riboside
Common side effects
- mild GI upset (rare)
- headache (rare)
Contraindications
- pregnancy / lactation (insufficient data)
- active cancer (theoretical, no contraindicating data)
Interactions
- pterostilbene: complementary sirtuin pathway (Basis combination)(minor)
- TMG (trimethylglycine): methylation support during high NAD+ precursor dosing(minor)
Which Should You Take?
Nicotinamide Riboside comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Armodafinil is the right call when one of the conditionals below applies.
- → If your priority is wakefulness, pick Armodafinil.
- → If your priority is focus or working memory, pick Armodafinil.
- → If your priority is healthspan extension, pick Nicotinamide Riboside.
- → If your priority is energy and stamina, pick Nicotinamide Riboside.
Edge case: If you want to avoid controlled substance, Nicotinamide Riboside is the more accessible choice.
Default choice: Nicotinamide Riboside. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Armodafinil only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Armodafinil and Nicotinamide Riboside?
Armodafinil and Nicotinamide Riboside differ in category (pharmaceutical vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Armodafinil or Nicotinamide Riboside?
Armodafinil half-life is 15 hours; Nicotinamide Riboside half-life is 8 hours.
Can you stack Armodafinil with Nicotinamide Riboside?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper